Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
3 results loaded, newest first. End of these results.
Novocure announced MHLW approval of Optune Pax for unresectable locally advanced pancreatic cancer, to be used with gemcitabine and nab—paclitaxel.Key Highlights:Original SEC Filing: NovoCure Ltd [ NVCR ] - 8-K - Oct. 01, 2026This is an AI-powered summary. It may contain inaccuracies. Consider veri…
Novocure's Optune Pax has received approval from Japan's MHLW for adult patients with unresectable locally advanced pancreatic cancer. The approval is for use in combination with gemcitabine and nab-paclitaxel, following positive results from the Phase 3 PANOVA-3 trial which demonstrated improved median overall surviva
Novocure announced that Japan's Ministry of Health, Labour and Welfare approved Optune Pax for adult patients with unresectable locally advanced pancreatic cancer, when used concomitantly with gemcitabine and nab-paclitaxel.